BioAtla

BioAtla

BioAtla, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. It focuses on developing Conditionally Active Biologic (CAB) antibody therapeutics. The company was founded to leverage proprietary protein engineering technologies designed to produce antibodies that are active only in the tumor microenvironment, potentially reducing systemic toxicity. BioAtla went public via an initial public offering in late 2020, listing on Nasdaq under the ticker BCAB. As a publicly traded operating company, it raises capital through equity offerings and partnership agreements to fund its clinical trials rather than managing assets for third-party investors or a single family. The company does not operate as a capital allocator, family office, or fund manager. Its financial resources are directed internally toward research and development of its pipeline candidates, which include CAB-AXL-ADC, CAB-ROR2-ADC, and CAB-CTLA-4. BioAtla has historically entered into strategic collaborations with larger pharmaceutical companies to co-develop its candidates in exchange for upfront payments, milestone payments, and research funding. These arrangements serve as its primary deployment mechanisms rather than external investments. Given BioAtla's status as an operating biotech firm, standard Altss metrics such as assets under management, investment team headcount, or allocator strategy do not apply. The company has no disclosed AUM, no investment professionals in the traditional allocator sense, and no fund vehicles. Its scale is measured by market capitalization, cash runway, and clinical trial progress. As of its latest regulatory filings, BioAtla operates primarily from its San Diego headquarters. BioAtla's structural architecture as a clinical-stage biotech places it entirely outside the family office and asset manager categories that Altss evaluates. The company's governance follows a standard public-company model with a board of directors and executive leadership team. Its financial lifecycle depends on clinical data readouts, partnership deals, and secondary equity offerings. It does not allocate capital to external managers, participate in co-investments, or manage wealth for a founding family.